| Project/Area Number |
25670406
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Kidney internal medicine
|
|---|
| Research Institution | Tokyo Medical and Dental University |
|---|
Principal Investigator |
UCHIDA SHINICHI 東京医科歯科大学, 医歯(薬)学総合研究科, 教授 (50262184)
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 高血圧 / 創薬 / キナーゼ / ケミカルライブラリー / キナーゼ阻害薬 |
|---|
| Outline of Final Research Achievements |
WNK- STE20/SPS1-related proline-alanine-rich protein kinase (SPAK)-SLC12a transporters cascade regulates blood pressure through NaCl reabsorption in kidney and vasoconstriction. Therefore, drugs that inhibit this signal cascade could become new antihypertensive drugs that have dual effects as a diuretic and vasodilator. We sought to discover SPAK kinase inhibitors by screening chemical compounds and existing drugs. We developed a new screening system using enzyme-linked immunosorbent assay (ELISA) and screened over 20,000 small-molecule compounds. As a result of this screening effort, we discovered one small-molecule compound and Closantel, an antiparasitic agent, which inhibited SPAK-regulated NCC and NKCC1 phosphorylation and activation not only in vitro but also in cultured cell lines and in mice.
|
